CVS Specialty Pharmacy

Overview

CVS Specialty Pharmacy is the specialty dispensing arm of CVS Health, paired with CVS Caremark, Aetna, Coram, and the CVS retail pharmacy network. It is a scaled, PBM-integrated specialty channel — the largest U.S. specialty pharmacy by dispensing revenue with a 200+ limited-distribution drug network, CVS-reported rare-disease and CGT product depth, and walk-in specialty pharmacy locations.

CVS Specialty is NOT a PBM-neutral specialty pharmacy, an independent rare-disease boutique, or a stand-alone hub. It is most compelling when a launch needs broad payer access, oncology or rare-disease specialty workflows, retail or walk-in patient options, and possible Coram infusion coordination. It is less clean when a manufacturer wants PBM-neutral channel governance or wants to avoid Caremark / Aetna entanglement in access, data, and steering discussions.

Specialty Pharmacy Capability Model

The framework below standardizes how Rx Almanac evaluates specialty-pharmacies capabilities, so buyers can compare vendors like-for-like while the readout column stays vendor-specific. For this table, CVS Specialty Pharmacy is evaluated as specialty dispensing arm of CVS Health, paired with CVS Caremark, Aetna, Coram, and the CVS retail pharmacy network.

Capability	Buyer should compare	CVS Specialty Pharmacy readout
Specialty dispensing and channel access	Licensed dispensing footprint, payer network access, LDD participation, referral capture, and ability to serve the target patient geography.	Major fulfillment handoff. CVS Specialty is one of the largest U.S. specialty pharmacies, with Caremark adjacency and 200+ limited-distribution drug participation cited in company materials and industry reporting.
Benefits, PA, and reimbursement support	Benefit investigation, PA support, appeals coordination, copay/PAP routing, and reimbursement troubleshooting at the pharmacy edge.	Major coverage workflow. CVS Specialty emphasizes benefit review, affordability support, manufacturer copay and foundation routing, and prior-authorization workflow support.
Clinical therapy management and adherence	Pharmacist counseling, disease-specific protocols, refill outreach, injection training, persistence programs, and clinical escalation.	Major engagement model. Therapy-specific CareTeams cover oncology, rare disease, fertility, CGT, and other complex conditions; CVS-reported metrics include high digital-communication enrollment and oncology MPR benchmarks.
Cold chain, REMS, and complex handling	Temperature control, REMS certification, hazardous/controlled-substance handling, biologics, CGT, and other special distribution requirements.	CGT-relevant, confirm in RFP. CVS describes a Cell and Gene Therapy Experience Center, payer education, ultra-cold infrastructure where storage is needed, and access to 14 CGT products; confirm product-specific requirements.
Manufacturer data and outcomes reporting	Status feeds, dispense data, adherence/outcomes reporting, inventory visibility, and reporting cadence suitable for launch governance.	Confirm reporting layer in the RFP. CVS Specialty’s Real-Time Status Portal supports rare-disease referral updates and manufacturer reporting; define feed, cadence, field list, and data firewalling before award.
Site-of-care, infusion, or health-system coordination	Home infusion, ambulatory infusion, provider-office coordination, health-system capture, and buy-and-bill support where relevant.	Differentiated adjacency. Coram gives CVS a home-infusion lane that mail-only specialty pharmacies cannot match directly.

Buyer Fit

• Where to use it: Include CVS Specialty when a national specialty launch needs Caremark / Aetna payer alignment, scaled LDD participation, oncology or rare-disease CareTeams, retail and walk-in patient routing, and optional Coram infusion coordination.
• Profile signal: Largest U.S. specialty pharmacy by dispensing revenue, 200+ LDD products, rare-disease portal reporting, CVS-reported CGT product access, walk-in specialty locations, and CVS Health-owned PBM, payer, and retail adjacency.
• Best-fit therapies: Oncology, rare disease, fertility, immunology, PAH, CGT, and other specialty launches where the manufacturer needs a high-scale dispensing partner with Caremark access, therapy-specific clinical workflows, and retail or walk-in options.
• Less ideal fit: Manufacturers seeking a PBM-neutral specialty channel, ultra-rare concierge models, or clean separation between manufacturer services, payer economics, and PBM formulary decisioning.
• Commercial fit: Pricing is undisclosed; assume an RFP-led scope with service levels, data feeds, firewalling commitments, and CVS Health cross-business coordination defined in the SOW.
• Coverage diligence: Caremark / Aetna data firewalling, LDD participation versus competitor SP routing, walk-in fulfillment economics, and the dividing line between CVS Specialty and Coram for any product that touches both pharmacy and infusion.

Differentiators

• Scale and channel access: CVS Specialty sits inside CVS Health’s pharmacy, PBM, payer, and retail stack, which can create major access reach for products where Caremark alignment matters.
• Physical specialty footprint: The 23 walk-in specialty pharmacy locations give CVS a patient-facing option for complex conditions near major care communities.
• Oncology depth: Public CVS Specialty materials describe oncology-dedicated pharmacy teams, 250+ oncology medications, REMS support, EHR connectivity, affordability review, and broad oncology prescriber usage.
• Rare-disease CareTeams and portal reporting: CVS Specialty publishes a CoE model for complex, rare, and ultrarare diseases, trained clinical teams, near-real-time referral updates, custom statuses, and manufacturer reporting through the Real-Time Status Portal.
• CGT access infrastructure: Current CVS materials describe payer-relations support, treatment-center logistics education, ultra-cold infrastructure where needed, drive-through dispensing, and access to 14 cell and gene therapy products from CVS’s March 2026 tracking.
• Coram adjacency: Coram is a practical differentiator for manufacturers evaluating specialty pharmacy plus infusion or home-administration pathways.

RFP Questions

• Which payer, LDD, retail, and health-system channels can CVS Specialty actually access for this product?
• How will CVS separate manufacturer reporting and patient support from Caremark / Aetna formulary, utilization-management, and payer decisioning?
• What benefit-investigation, PA, appeal, affordability, and triage workflow is therapy-specific rather than generic?
• What happens when the payer requires a non-CVS dispensing pharmacy after CVS receives the script?
• Which Coram or infusion workflows are in scope, and which remain separate from the specialty pharmacy agreement?
• What data fields, timing, exceptions, and service-level metrics will be included in launch governance reporting?
• What Real-Time Status Portal fields, rare-disease LDD statuses, CGT case-management views, and digital-communication metrics will the manufacturer receive?
• How will transparent PBM, cost-plus, or rebate-delinking models affect the specialty economics presented to the manufacturer?

Recent Activity

• 2026: Current CVS Specialty rare-disease materials emphasized the Real-Time Status Portal, custom referral statuses, hub-program collaboration, and access to approximately 220 rare-disease LDDs including nearly 40 ultrarare products.
• 2026: Current CVS Specialty CGT materials described the Cell and Gene Therapy Experience Center, payer-relations support, ultra-cold infrastructure where needed, drive-through dispensing, and access to 14 CGT products from CVS’s March 2026 tracking.
• 2026: CVS Specialty materials emphasized oncology workflows, EHR connectivity, walk-in specialty pharmacy locations, and therapy-specific CareTeams.
• 2025-2026: CVS Health promoted fertility access through CVS Specialty, dedicated fertility pharmacists, financial-options review, retail pickup, mail delivery, and temperature-controlled packaging.
• 2026: CVS Caremark reached a proposed FTC insulin settlement requiring delinking of certain Caremark compensation from rebate negotiations, reinforcing the need to diligence PBM-owned specialty economics.
• 2025: CVS Health continued to frame pharmacy, PBM, payer, and retail integration as the operating model for access and affordability.